ViaCyte Stock
Preclinical Therapeutic Company
Sign up today and learn more about ViaCyte Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About ViaCyte Stock
ViaCyte formerly Novocell is a preclinical therapeutic company focused on diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrates that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.
Funding History
| 2006-05-01 | $20.0M |
|---|---|
| 2007-07-01 | $25.0M |
| 2013-07-01 | $10.6M |
| 2014-08-01 | $20.0M |
| 2014-08-01 | $5.4M |
| 2014-09-01 | $16.6M |
| 2016-07-01 | $3.9M |
| 2017-05-01 | $10.0M |
| 2018-09-01 | $10.0M |
| 2018-11-01 | $80.0M |
Management
Senior Vice President, Science & Technology
Allan Robins
Vice President, Business Development and Strategy
Mark Zimmerman
Director
Steven R. Altman
President and Chief Executive Officer
Paul Laikind
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
